Immuneering (NASDAQ:IMRX) Downgraded to “Sell” Rating by Wall Street Zen

Immuneering (NASDAQ:IMRX) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Monday.

Other analysts have also issued research reports about the company. Chardan Capital reissued a “buy” rating and set a $20.00 price target on shares of Immuneering in a report on Tuesday, May 19th. Cantor Fitzgerald assumed coverage on Immuneering in a research note on Wednesday, July 8th. They issued an “overweight” rating and a $17.00 price objective on the stock. Oppenheimer reaffirmed an “outperform” rating on shares of Immuneering in a research report on Monday, June 1st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Immuneering in a research note on Wednesday, June 24th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $16.57.

Immuneering Price Performance

Shares of IMRX stock opened at $4.64 on Monday. The company has a market cap of $300.21 million, a price-to-earnings ratio of -3.97 and a beta of 0.41. Immuneering has a 1 year low of $2.90 and a 1 year high of $10.08. The firm has a fifty day moving average price of $4.83 and a 200-day moving average price of $5.12.

Immuneering (NASDAQ:IMRX) last announced its earnings results on Friday, May 15th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.09. Equities research analysts expect that Immuneering will post -1.09 EPS for the current year.

Institutional Investors Weigh In On Immuneering

Institutional investors have recently bought and sold shares of the business. Jane Street Group LLC bought a new stake in Immuneering during the first quarter valued at about $32,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Immuneering in the fourth quarter worth about $33,000. Levin Capital Strategies L.P. purchased a new stake in shares of Immuneering during the first quarter worth about $53,000. Focus Financial Network Inc. purchased a new stake in shares of Immuneering during the second quarter worth about $62,000. Finally, Cetera Investment Advisers bought a new stake in Immuneering during the 1st quarter valued at approximately $67,000. Hedge funds and other institutional investors own 67.65% of the company’s stock.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.